Tonsil explants as a human


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 29 04 2024
accepted: 28 08 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: epublish

Résumé

Vaccination is one of the most effective infection prevention strategies. Viruses with high mutation rates -such as influenza- escape vaccine-induced immunity and represent significant challenges to vaccine design. Influenza vaccine strain selection is based on circulating strains and immunogenicity testing in animal models with limited predictive outcomes for vaccine effectiveness in humans. We developed a human Tonsils cultured in bioreactors showed higher viability, metabolic activity, and more robust immune responses than those in static cultures. The Perfusion-cultured tonsil tissue may be a valuable human

Identifiants

pubmed: 39355250
doi: 10.3389/fimmu.2024.1425455
pmc: PMC11442277
doi:

Substances chimiques

Influenza Vaccines 0
Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1425455

Informations de copyright

Copyright © 2024 Bonaiti, Muraro, Robert, Jakscha, Dirnhofer, Martin and Berger.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision

Auteurs

Elena Bonaiti (E)

Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Manuele G Muraro (MG)

Tissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.

Philippe A Robert (PA)

Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Jens Jakscha (J)

Ear Nose Throat Clinic, University Hospital Basel, Basel, Switzerland.

Stefan Dirnhofer (S)

Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Ivan Martin (I)

Tissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland.

Christoph T Berger (CT)

Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
University Center of Immunology, University Hospital Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH